
- Oncology NEWS International Vol 15 No 8
- Volume 15
- Issue 8
FDA Approves Oncaspar for First-Line ALL
The FDA has granted expanded approval to Enzon's Oncaspar (pegaspargase) as part of multidrug chemotherapy for treating children and adults with newly diagnosed acute lymphoblastic leukemia (ALL
ROCKVILLE, MarylandThe FDA has granted expanded approval to Enzon's Oncaspar (pegaspargase) as part of multidrug chemotherapy for treating children and adults with newly diagnosed acute lymphoblastic leukemia (ALL). The agency acted on the basis of results from a randomized, 118-patient pediatric study that showed Oncaspar was equivalent in safety and efficacy to Elspar (L-asparaginase, Merck), which has been the standard treatment for ALL.
Use of Oncaspar reduces the number of injections required during a 20-week course of treatment to 3, compared to the 21 injections needed for Elspar. Oncaspar was initially approved in February 1994 for the treatment of ALL patients unable to tolerate L-asparaginase because of allergic reactions.
To support the new indication, Enzon submitted results from two trials involving patients who had standard-risk ALL. FDA based its approval on Study 1, conducted by the Children's Cancer Group (CCG). Study 2, an ongoing, multifactoral design study also conducted by CCG, provided interim safety data from 2,770 pediatric patients with a median age of 4 years.
Study 1 was an active-control, open-label trial in which researchers randomized 118 patients (age 1.1 to 9.9 years) to receive Oncaspar or native E coli L-asparaginase. "In the trial, researchers demonstrated that Oncaspar could be safely and effectively substituted for Elspar as part of the multidrug cancer regimen," FDA said. Due to the risk of anaphylaxis and other serious allergic reactions, the drug's labeling warns physicians to observe patients for 1 hour after administering Oncaspar "in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis."
Articles in this issue
about 19 years ago
Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcomeabout 19 years ago
Higher Responses in Metastatic Colon Ca When Cetuximab Added to Chemoabout 19 years ago
Triple Targeted Therapy Is Tested in Pts With Solid Tumorsabout 19 years ago
FDA Approves Three-Drug Combination Tablet for HIV-1about 19 years ago
Side Effects Persist 16 Years After Prostate Ca Brachytherapyabout 19 years ago
No Significant QOL Differences for Raloxifene and Tamoxifenabout 19 years ago
Amrubicin Appears Promising in Small-Cell Lung Cancerabout 19 years ago
R-MP Active in Older Pts With Newly Diagnosed Myelomaabout 19 years ago
Sunitinib and Sorafenib Active in Phase II Advanced NSCLC Trialsabout 19 years ago
Takeda Signs Agreement With Galaxy Biotech for HuL2G7Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.